thyssenkrupp nucera (NCH2) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
26 May, 2026Executive summary
Q2 order intake surged to EUR 316 million, nearly quadrupling year-over-year, driven by major green hydrogen and chlor-alkali projects, with order backlog rising to EUR 732 million by March 2026.
Major new contracts include a 300 MW electrolyzer in Spain, a 260 MW FEED study in India, and a record chlor-alkali order in the Middle East.
Innovative offerings launched, including a 360-degree lifecycle service portfolio and a 120 MW plug-and-play electrolyzer system.
Quarterly financials were significantly impacted by one-time project costs, special items, and a contract termination in green hydrogen, but these are not expected to recur in the second half.
Strategic cost containment and efficiency programs launched to address market softness and improve competitiveness.
Financial highlights
Q2 order intake reached EUR 316 million (+279% YoY), with green hydrogen at EUR 176 million and chlor-alkali at EUR 140 million; order backlog at EUR 732 million.
Q2 sales declined 77% year-on-year to EUR 50 million, mainly due to one-time effects and project-specific cost overruns in green hydrogen; 6M sales at EUR 197 million (-59% YoY).
Q2 EBIT was EUR -65 million (vs. EUR -4 million prior year), driven by EUR 78 million EBIT loss in green hydrogen; 6M EBIT at EUR -69 million.
Q2 net income was EUR -64 million; EPS at EUR -0.50; 6M net income at EUR -66 million, EPS at EUR -0.53.
Free cash flow for 6M was EUR 3 million; Q2 free cash flow improved to EUR 9 million; net financial assets stable at EUR 655 million.
Outlook and guidance
Full-year 2025/26 order intake expected at EUR 550–850 million, sales at EUR 450–550 million, and EBIT at EUR -80 to -30 million.
Green hydrogen segment sales expected at EUR 120–170 million, EBIT at EUR -125 to -90 million; chlor-alkali sales at EUR 320–400 million, EBIT at EUR 45–65 million.
One-time effects from green hydrogen will impact this year’s results, but operational performance and guidance remain sound.
Latest events from thyssenkrupp nucera
- Industrial-scale electrolysis leader with strong growth, innovation, and ESG focus.NCH2
Investor presentation13 May 2026 - Strong financials, strategic innovation, and all agenda items approved amid market challenges.NCH2
AGM 202610 Apr 2026 - Order intake guidance raised to €550–850m, but sales and EBIT guidance lowered for FY 2025/26.NCH2
Status update18 Mar 2026 - Record chlor-alkali sales and improved margins offset green hydrogen softness; outlook cautious.NCH2
Q4 202513 Feb 2026 - Sales and EBIT declined sharply, but full-year guidance and order momentum remain strong.NCH2
Q1 202611 Feb 2026 - Record sales and robust backlog, but AWE outlook clouded by regulatory and market delays.NCH2
Q3 20241 Feb 2026 - Record sales and resilient AWE and CA growth drive strong performance amid market challenges.NCH2
Q4 202411 Jan 2026 - Record Q1 sales and EBIT growth, with strong outlook and robust order backlog.NCH2
Q1 202523 Dec 2025 - Q3 sales fell, but raised guidance and margin gains highlight improved outlook.NCH2
Q3 202523 Nov 2025